ADAMTS13 and COVID-19: Viral infections are recognized as prominent triggers for TTP, acting through mechanisms such as direct endothelial injury and the induction of autoantibodies against ADAMTS13 [11] The hypercoagulable state observed in COVID‐19 has also been linked to cytopathic endothelial damage, possibly mediated via entry through the ACE‐2 receptors [12].